(CML). 1,2 HLA-identical sibling donors are available for only about 30-40% of patients and, in the absence of suitable sibling donors, alternative stem cell sources may be Within the registry of the chronic leukaemia working party of the European Group for Blood and Marrow sought, ie HLA-identical unrelated volunteer donors (marrow or cord blood) 3,4 and haploidentical family memTransplantation, data were available from 103 patients with chronic myeloid leukaemia who were treated by bers. 5 However, despite improvements in the transplant outcomes in recent years, the results of transplants from bone marrow transplantation from haploidentical family members. The patients of median age 30 years were donors other than HLA-identical siblings are associated with a high incidence of complications, such as primary transplanted between 1983 and 1994 in 25 European centres. The overall probabilities of survival and leuand secondary graft failure, severe acute and chronic graftversus-host disease (GVHD) and viral infections. 6-8 It is not kaemia-free survival (LFS) at 5 years were 32 and 25%, respectively. In univariate analysis, two factors were yet clear whether there are differences in outcome between recipients of volunteer unrelated donor marrow and those identified which affected survival and LFS, ie the state of disease at the time of transplant and the degree of who receive haploidentical marrow from family members. Anasetti et al 9 have suggested that the use of haploidentical HLA disparity. Fifty-nine patients were transplanted in first chronic phase and the probability of survival at 2 related marrow with no more than a single HLA-A, -B, or -DR mismatch provides clinical results comparable to HLA years was 47%. Forty-four patients received their transplants for advanced disease and their probability of surgenotypically identical sibling BMT. Ideally, prospective randomised studies comparing these two alternative donor vival at 2 years was 25% (P = 0.004). Donor bone marrow was HLA-mismatched for 0-1 antigens in 54 sources should provide the necessary information for optimal donor selection. In practice however, such studies canpatients (group 1) and for 2-3 antigens in 49 patients (group 2). At 2 years, the probabilities of survival for not be performed. Therefore, retrospective analysis of data continues to play an important role in the evaluation of groups 1 and 2 were 46 and 27% (P Ͻ 0.02) and the probabilities of LFS were 43 and 24% (P Ͻ 0.03), donor selection. In order to determine the outcome of haploidentical famrespectively. Multivariate analysis confirmed the prognostic importance of the disease stage and of the HLA ily member transplants, we have analysed the results from 103 such patients with CML reported to the Chronic Leudisparity. Patients transplanted in first chronic phase from a donor mismatched for 0-1 HLA antigens had a kaemia Registry of the European Group for Blood and Marrow Transplantation (EBMT). This allowed a retrospective probability of survival of 52% at 2 years compared with 19% for patients transplanted in advanced disease stage evaluation of possible risk factors such as advanced patient or donor age, transplantation in advanced disease stage, or from donors mismatched for 2-3 HLA antigens. Keywords: CML; BMT; haploidentical family donors; mismatches for sex or HLA antigens. Further aims of this study were the search for clinically acceptable HLA mis-GVHD matches and the comparison of HLA class 1 with class 2 mismatches.
121 patients transplanted for CML from haploidentical vent GVHD. The incidence and severity of GVHD were defined by the criteria described by Glucksberg et al. 12 family members. Full data concerning the HLA types of the recipients and their donors were available for 103 of the 121 patients and our analysis was therefore restricted Statistics to these individuals. Any additional information required was requested directly from the 25 centres involved in the Differences in patient characteristics and the incidence of transplants. The patients were transplanted between 1983 acute GVHD between the two groups were compared using and 1994 and the analysis was completed from information the 2 or Mann-Whitney tests as appropriate. Transplantavailable as of October 1995. For the 33 patients alive at related mortality (TRM), leukaemic relapse, survival and last assessment, the median follow-up was 36 months LFS were calculated according to Kaplan and Meier. 13 A (range .
series of characteristics were studied for their possible Details of the total population and of two groups of effect on outcome using the log-rank test, 14 ie patient age patients divided according to the degree of HLA-disparity at transplant, donor age at transplant, patient sex, donor sex, between recipient and donor (group 1, 54 patients patient-donor relationship, disease stage at transplant and transplanted from donors mismatched for 0-1 HLA antidegree of HLA disparity. All variables recognised as gens, and group 2, 49 patients transplanted from 2-3 HLA possible prognostic factors were studied using the Cox antigen mismatched family members) are given in Table 1. proportional hazard regression model. 15 In the majority of cases, HLA-typing was performed using standard serological techniques for HLA-A, B, DR. DNA oligotyping results for HLA-DR 10, 11 were available for 11 Results patients. Nine patients received phenotypically identical marrow. Thirty-four patients received marrow mismatched for class 1 antigens only, 19 patients were given marrow Characteristics of the patients are provided in Table 1 . Patients in groups 1 and 2 were not strictly comparable. mismatched for class 2 antigens only and the remaining 41 patients received marrow mismatched for both class 1 and Patients in group 1 were older than those in group 2 but were more likely to be transplanted in first chronic phase class 2 antigens (Table 2 ). Bone marrow transplantation was performed according to local treatment protocols. The (CP) and to receive unmanipulated bone marrow than those in group 2. Similarly, patients transplanted in first chronic majority of patients received total body irradiation (TBI, 96%) and cyclophosphamide (96%). Forty-eight percent of phase differed in several important respects from those transplanted for advanced phase disease. The latter tended the patients received marrow which had been depleted of T cells prior to infusion. Ninety-three percent of the to be younger than patients treated in first CP, but were more likely to receive marrow from donors mismatched for patients were given cyclosporin A alone (14%), or in combination with methotrexate (36%), T cell depletion (TCD, 2-3 HLA antigens and to receive cells which had been depleted of T cells prior to infusion. 33%) or TCD and methotrexate (10%) in an attempt to pre- Characteristics of the 103 patients studied. All patient-donor pairs were related and shared one HLA haplotype. Thus, they were genotypically identical for 1A, 1B, and 1DR antigen. HLA mismatches (mm) indicate the number of mismatched HLA-A, B, DR antigens, whereby 0 is the minimum and 3 the maximum. The data are either numbers of patients or else as indicated in parenthesis. AP = accelerated phase; BC = blast crisis. 13 Probabilities at 5 years could not be determined due to low patient numbers. The P values are from comparisons of the three groups. The differences between class 1 vs class 2 mismatches were all not significant (P values not shown). Table 3 Clinical outcome in relation to the number of HLA Eighty-two (80%) patients engrafted ( Table 3 ). The incimismatches dence of graft failure was higher in recipients of T celldepleted transplants at 33% than in recipients of unmanipu- Acute GVHD
Engraftment

Graft-versus-host disease
Seventy-nine patients were evaluable for acute GVHD III-IV 30 (38%) 13 (28%) 17 (52%) 0.09 (Table 3) . Severe acute GVHD, defined as grade III-IV, not evaluable 24 8 16 showed a tendency to be more common in patients who received unmanipulated marrow (34%) than in recipients 
Transplant-related mortality
The results for engraftment and GVHD are indicated in numbers of
The incidence of transplant-related mortality was influpatients (and percentages), the data for survival, LFS, relapse, and TRM are probabilities determined by the method of Kaplan and Meier. 13 enced by the degree of HLA disparity between the recipient and their donor. Patients who were mismatched for 0-1 causes of death were GVHD (24 patients) and infection (23 patients) . Other fatal complications included HLA antigens had a TRM of 43% compared with 67% for those recipient-donor pairs mismatched for 2-3 antigens pneumonitis/ARDS, leukaemic relapse, graft failure/ rejection, veno-occlusive disease and haemorrhage. (P Ͻ 0.05) indicating that severe treatment-related complications occurred more frequently after transplantTwenty-one patients relapsed, of whom six survived. Death in the absence of relapse, ie transplant-related mortality ation across more than one HLA mismatch. occurred in 55 patients. Survival and LFS were influenced by two factors, the Leukaemic relapse stage of the disease at the time of transplant and the degree of HLA disparity between donor and recipient. The survival There was a trend towards an increase in leukaemic relapse in patients who were transplanted for advanced phase disand LFS at 2 years for patients transplanted in first CP were 47 and 43%, compared with 25 and 23% for those treated ease compared to those treated in first CP (30 vs 25%, P = NS), in patients transplanted after a time interval for advanced phase disease. The survival and LFS at 2 years for the 54 patients transplanted from donors misbetween diagnosis and transplant which was greater than the median (P = NS), in patients who received T cellmatched for 0-1 HLA antigens were 46 and 43%, and 27 and 24% of those who received 2-3 HLA-antigen misdepleted marrow compared to recipients of unmanipulated cells (45 vs 26%, P = NS) and in patients transplanted from matched marrow (survival P = 0.02, LFS P = 0.03). The outcome of the nine patients transplanted from phenodonors for 2-3 HLA antigens compared to those transplanted using 0-1 HLA-antigen mismatched marrow typically HLA identical donors was not significantly different from those transplanted using marrow mismatched for (P = NS). However, patients transplanted with advanced disease, a factor known to predispose to relapse, were also one HLA antigen (data not shown). more likely to have received T cell-depleted cells and/or marrow mismatched for 2-3 HLA antigens, and to have
Comparison of patients transplanted with HLA class 1, been transplanted beyond the median time from diagnosis class 2, or class 1 + 2 mismatched donors to transplant.
To investigate the importance of the two classes of HLA antigens, we alternatively grouped the patients in those misSurvival and leukaemia-free survival matched for HLA class 1 (HLA-A and/or -B), class 2 (HLA-DR), or class 1 + 2 mismatches (Table 2 ). In a simiThe probabilities of survival and leukaemia-free survival for the 103 patients were 37 and 34% at 2 years, and 32 lar way to the patients with 2-3 HLA mismatches presented above, the patients with class 1 + 2 mismatches were sigand 25% at 5 years (Table 3 and Figure 1 ). At the time of the last assessment, 33 patients were still alive with a nificantly younger and they were more often transplanted in advanced disease stage. The incidence of acute GVHD median follow-up of 36 months (range 6-107). The main did not differ significantly between the three groups. There was a trend (which was not significant) for less leukaemia relapse in the patients with class 1 or class 2 mismatches as compared with those with combined class 1 + 2 mismatches, but the latter were more often transplanted in advanced disease stage. Engraftment, TRM, survival, and LFS correlated significantly with the class of HLA mismatches. Importantly, the comparison of the first two columns in Table 2 , ie patients mismatched for class 1 vs class 2 did not reveal significant differences for any of the indicated parameters.
Multivariate analysis
There were a number of important differences in patient characteristics between patients with different degrees of HLA mismatches and between patients transplanted in first CP and those treated for advanced disease. In order to determine the prognostic values of factors known to influence transplant outcomes, we performed a six-parameter multivariate analysis which included stage of disease at BMT, the degree of HLA disparity, the use of T cell depletion, donor and patient age and recipient-donor sex mismatching. The most important parameter for survival and LFS was the stage of disease at transplant. The degree of HLA disparity correlated with survival but was not Using the two significant parameters for clinical out- Cox's regression analysis on survival and leukaemia-free survival, with stage of disease at BMT, HLA-mismatch, T cell depletion, age of patient, age of donor, and sex mismatch as covariables. Eighty-eight patients with complete data sets could be included in this analysis. RR = relative risk, CI = confidence interval.
come, ie stage of disease at transplant, and the degree of HLA disparity, we classified the patients into four groups according to these criteria. At 2 years post-transplant, the probability of LFS for patients transplanted in first CP from donors mismatched for only 0-1 HLA antigens was 50% compared with 22% for patients transplanted for advanced phase disease using marrow mismatched for 2-3 HLA antigens (P = 0.004, Figure 2 ).
Discussion
This study confirms the importance of disease stage 16 and HLA compatibility 9 as prognostic factors for the clinical outcome after allogeneic bone marrow transplantation. In contrast, TCD, age of patient and donor, and sex mismatch did not signficantly correlate with disease outcome.
The most important parameter was the disease stage at the time of transplantation. This is a well known finding confirmed for the outcome of all known transplants. The relatively high percentage of patients transplanted in advanced disease in this study may in part be explained by the longer delay between diagnosis and transplantation in earlier years. In fact, the median delay in the 56 patients grafted between 1983 and 1988 was 608 days and thus slightly longer than the 563 days of the 47 patients grafted between 1989 and 1994. During the earlier period, 50% of the patients were in first chronic phase contrasting with 66% afterwards. The median delay in this study was longer transplant early, ideally during the first year after diagnosis.
However, the decision to transplant a patient is particularly matching have been reported which may in part be explained by the known technical difficulties to routinely difficult when there is no optimal donor available. The consideration of alternative treatments, 18, 19 autologous BMT, 20 detect many of the existing HLA subtypes. Therefore, in future transplants HLA-A, -B and -DR antigens should be or unrelated BMT 21 probably prolonged the delay in several of our patients.
typed by precise molecular, biochemical and cellular techniques. 26, 28 HLA-C, -DQ, -DP should also be monitored, Engraftment was significantly better in the group with 0-1 HLA mismatches. However, no firm conclusion can be since the six classical histocompatibility antigens are all highly polymorphic and show a strong linkage disequilibdrawn since this group contained more transplants in the first chronic phase and more T cell non-depleted grafts.
rium. In theory, haploidentical transplants are better suited than unrelated donor-patient pairs for studies assessing the Interestingly, we did not find a statistically significant correlation between the number of HLA mismatches and acute role of mismatches at individual HLA loci, since there is always a genotypic identity for one of the two haplotypes GVHD. This may indicate that multiple HLA mismatches do not increase the risk for acute GVHD. However, and mismatches of minor transplantation antigens may be less frequent. Therefore, incompatible antigens are easier we speculate that strong GVHD prophylaxis, the frequent incidence of complications other than GVHD, and the to characterise and less frequent in haploidentical-related pairs as opposed to unrelated pairs. Our initial project for relatively low number of patients may have obscured a correlation between HLA matching and acute GVHD.
this study was to search for clinically acceptable HLA mismatches. The present data however did not allow identifiSex matching did not influence the clinical outcome in this study, possibly due to reasons similar to those stated cation of such HLA mismatches. We also attempted to compare major (eg A2 vs A3) with minor (eg A2 vs A28) above in the discussion for GVHD. Alternatively, sex matching known to potentially influence the outcome in mismatches and to evaluate NIMA and NIPA HLA mismatches (non-inherited maternal/paternal antigens). Unfor-HLA phenotypically identical BMT 22 may be less important in HLA-mismatched grafts. Possibly, mismatches tunately, the patient numbers were too small for reasonable comparisons. Hopefully, such investigations will become of major transplantation antigens may have a dominant effect on post-transplant complications such that additional more successful in the future when large numbers of patients are analysed in detail. mismatches of minor transplantation antigens (eg the male specific antigen H-Y) may not cause the immune reactions In summary, our study confirms that patients should be transplanted in the first chronic phase preferably with less observed in HLA-matched BMT.
Transplant-related mortality was relatively high in this than two HLA mismatches. In contrast, transplantation after the first chronic phase or with multiple HLA-ABDR misstudy thus confirming the increased risk for complications associated with HLA-mismatched transplantation. [7] [8] [9] The matches is associated with frequent transplant-related complications and should therefore be considered as expericlinical outcome was significantly better in the group with 0-1 HLA mismatches as opposed to those with 2-3 HLA mental. Our conclusions apply for BMT using conventional irradiation, cyclophosphamide treatment, and standard mismatches. However, the latter were more likely to be in advanced phase of the disease and more likely to be numbers of donor marrow cells. Hopefully, modifications of treatment protocols may increase the success rate with transplanted with T cell-depleted marrow. On the other hand, these patients were younger. The multivariate HLA-incompatible donors. One example may be the transplantation of high numbers of T cell-depleted mobilised analysis allowed compensation for these group differences and confirmed the correlation of the number of HLA peripheral blood cells which has been reported to improve clinical results in Ͼ1 HLA-mismatched BMT.
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mismatches with patient survival. The survival of 52% and the leukaemia-free survival of 50% (both at 2 years) in patients transplanted in the first Acknowledgements chronic phase with 0-1-mismatched bone marrow shows the relatively good prognosis in this situation. tation. 7 However, controversial data on the role of HLA
